Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Vascular injury results in the activation of coagulation and the release of proteolytic enzymes from neutrophils and connective- tissue cells. High concentrations of these inflammatory proteinases may destroy blood coagulation proteins, contributing to coagulation and bleeding disorders associated with severe inflammation. Matrix metalloproteinase-8 (MMP-8) is released from neutrophils at sites of inflammation and vascular disease. We have investigated the effect of MMP-8 degradation on the anticoagulant function of tissue factor pathway inhibitor (TFPI) as a potential pathological mechanism contributing to coagulation disorders. MMP-8 cleaves TFPI following Ser(174) within the connecting region between the second and third Kunitz domains ( k (cat)/ K (m) approximately 75 M(-1).s(-1)) as well as following Lys(20) within the NH(2)-terminal region. MMP-8 cleavage of TFPI decreases the anticoagulant activity of TFPI in factor Xa initiated clotting assays as well as the ability of TFPI to inhibit factor Xa in amidolytic assays. Yet, MMP-8 cleavage does not alter the ability of TFPI to inhibit trypsin. Since the inhibition of both factor Xa and trypsin is mediated by binding to the second Kunitz domain, these results suggest that regions of TFPI other than the second Kunitz domain may directly interact with factor Xa. (125)I-factor Xa ligand blots of TFPI fragments generated following MMP-8 degradation were used for probing binding interactions between factor Xa and regions of TFPI, other than the second Kunitz domain. In experiments performed under reducing conditions that disrupt the Kunitz domain structure, (125)I-factor Xa binds to the C-terminal fragment of MMP-8-degraded TFPI. This fragment contains portions of TFPI distal to Ser(174), which include the third Kunitz domain and the basic C-terminal region. An altered form of TFPI lacking the third Kunitz domain, but containing the C-terminal region, was used to demonstrate that the C-terminal region directly interacts with factor Xa.
Cunningham
Anna C
AC
Department of Pathology, The University of Tennessee, Memphis, TN 38163, U.S.A.
Hasty
Karen A
KA
Enghild
Jan J
JJ
Mast
Alan E
AE
D000595:Amino Acid Sequence; D007611:Aprotinin / Q000737:chemistry; D001778:Blood Coagulation Disorders / Q000378:metabolism / Q000503:physiopathology; D015951:Factor Xa / Q000378:metabolism; D006801:Humans; D008074:Lipoproteins / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D020784:Matrix Metalloproteinase 8 / Q000235:genetics / Q000378:metabolism*; D008969:Molecular Sequence Data; D017434:Protein Structure, Tertiary; D014361:Trypsin Inhibitors / Q000494:pharmacology
D008074:Lipoproteins; D014361:Trypsin Inhibitors; C051928:lipoprotein-associated coagulation inhibitor; D007611:Aprotinin; D015951:Factor Xa; D020784:Matrix Metalloproteinase 8